Clinical significance of pmTOR expression in endometrioid endometrial carcinoma

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 153, Issue 2, 2010, Pages 207-210

  Choi, Chel Hun ^a   Lee, Ji Soo ^a   Kim, Seong Rim ^b   Kim, Tae Joong ^a   Lee, Jeong Won ^a   Kim, Byoung Gie ^a   Bae, Duk Soo ^a  

^a Sungkyunkwan University   (South Korea)

^b Medplan Pathology Laboratory Center   (South Korea)

Author keywords

Endometrial cancer; Immunohistochemistry; PmTOR

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ADULT; ARTICLE; CANCER INFILTRATION; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; EPITHELIUM CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MYOMETRIUM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 78249257742     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2010.07.038     Document Type: Article

References (19)

1. C.P. Morrow, B.N. Bundy, and R.J. Kurman Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study Gynecol Oncol 40 1991 55 65
2. M.E. Randall, V.L. Filiaci, and H. Muss Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study J Clin Oncol 24 2006 36 44
3. H.M. Keys, J.A. Roberts, and V.L. Brunetto A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study Gynecol Oncol 92 2004 744 751
4. E. Latta, and W.B. Chapman PTEN mutations and evolving concepts in endometrial neoplasia Curr Opin Obstet Gynecol 14 2002 59 65
5. D.M. Sabatini mTOR and cancer: insights into a complex relationship Nat Rev Cancer 6 2006 729 734
6. S. Huang, and P.J. Houghton Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic Curr Opin Investig Drugs 3 2002 295 304
7. D. Pectasides, E. Pectasides, and T. Economopoulos Systemic therapy in metastatic or recurrent endometrial cancer Cancer Treat Rev 33 2007 177 190
8. A. Gadducci, S. Cosio, and A.R. Genazzani Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies Crit Rev Oncol Hematol 58 2006 242 256
9. G. Fons, S.M. Hasibuan, J. van der Velden, and F.J. ten Kate Validation of tissue microarray technology in endometrioid cancer of the endometrium J Clin Pathol 60 2007 500 503
10. A. Noske, J.L. Lindenberg, and S. Darb-Esfahani Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis Oncol Rep 20 2008 1409 1417
11. S. Darb-Esfahani, A. Faggad, and A. Noske Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro J Cancer Res Clin Oncol 135 2009 933 941
12. H. Wahl, S. Daudi, and M. Kshirsagar Expression of metabolically targeted biomarkers in endometrial carcinoma Gynecol Oncol 116 2010 21 27
13. E. Petroulakis, Y. Mamane, O. Le Bacquer, D. Shahbazian, and N. Sonenberg mTOR signaling: implications for cancer and anticancer therapy Br J Cancer 94 2006 195 199
14. B. Herberger, H. Puhalla, and M. Lehnert Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma Clin Cancer Res 13 2007 4795 4799
15. V.K. Anagnostou, G. Bepler, and K.N. Syrigos High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma Clin Cancer Res 15 2009 4157 4164
16. K.S. Chadha, T. Khoury, and J. Yu Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma Ann Surg Oncol 13 2006 933 939
17. D.A. Guertin, and D.M. Sabatini An expanding role for mTOR in cancer Trends Mol Med 11 2005 353 361
18. A.C. Gingras, B. Raught, and N. Sonenberg Regulation of translation initiation by FRAP/mTOR Genes Dev 15 2001 807 826
19. J. Montagne, M.J. Stewart, H. Stocker, E. Hafen, S.C. Kozma, and G. Thomas Drosophila S6 kinase: a regulator of cell size Science 285 1999 2126 2129